Skip to main content

B-cell treatment linked to more gut immune cells in MS

By MS Buddy ·

Summarized from Science translational medicine, Jul 2026 · PubMed · DOI. AI-generated summary. Not medical advice.

Observational study · people with MS, a person without MS, and mice

Research by Tradite Neziraj, Anne-Katrin Pröbstel and 26 colleagues at the University of Toronto, Vrije Universiteit and 5 other institutions in Switzerland, Canada, the Netherlands and 2 other countries.

How does B-cell treatment affect gut-linked immune cells in MS?

Key Takeaway

During B-cell treatment, people with MS had more gut-linked immune cells in their blood and spinal fluid.

Cut-paper gut shape beside red and pale blue ribbons, each dotted with small matching circles.
Credibility
Interest
Share:1 min read

What They Found

Researchers tracked immune cells during treatment that removes B cells, a type of immune cell. They found more B cells linked to the gut in the blood and spinal fluid. Cell patterns suggested that some of these cells traveled from the gut to other parts of the body. Higher levels of two substances that help B cells survive and grow were linked to better outcomes during treatment. The study did not show whether the gut-linked cells caused those better outcomes.

Who Should Care and Why

Researchers studied people with MS, one person without MS, and mice with an MS-like disease. The human findings concern people with MS receiving treatment that removes B cells. The researchers examined blood, spinal fluid, and samples from the gut. Gut samples came from one person with MS receiving treatment and one person without MS. The findings may help explain immune changes seen during this treatment.

Important Considerations

You should know that gut samples came from only one person with MS and one person without MS. The abstract does not give the total number of people studied, and some spinal fluid findings came from earlier datasets. You cannot tell from this study whether the gut-linked cells improve MS outcomes.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in Science translational medicine by et al.. Reproduced from the PubMed record.

Therapy with anti-CD20 monoclonal antibodies is highly efficacious in various autoimmune diseases including multiple sclerosis (MS), a prototypic autoimmune inflammatory disease of the central nervous system (CNS). However, which B cell subsets and altered B cell-regulating factors mediate the clinical efficacy of anti-CD20 treatment is unclear. To address this gap in knowledge, we performed longitudinal high-dimensional single-cell transcriptomic and proteomic profiling of blood, cerebrospinal fluid (CSF), and intestinal samples from people with MS (pwMS), combined with immune profiling in a preclinical autoimmune encephalomyelitis model during anti-CD20 therapy. CSF analyses were performed using previously published datasets. Multisite intestinal profiling was conducted in one anti-CD20-treated patient with MS and one control participant. By applying algorithm-guided analyses of flow cytometry, single-cell transcriptomic, and immune receptor repertoire data, we found that anti-CD20 B cell depletion was associated with increased frequencies of regulatory mucosal-derived IgA-producing B cells in the periphery and CSF, together with increased B cell receptor clonal overlap between mucosal and systemic compartments, indicating enhanced trafficking of IgA B cells from gut mucosal tissues to the systemic circulation and the CNS. Moreover, we demonstrated that higher levels of B cell-activating factor and a proliferation-inducing ligand were related to favorable outcomes in pwMS during anti-CD20 treatment. Together, our findings suggest that mucosal immune regulatory mechanisms may be harnessed by anti-CD20 B cell depletion, opening previously unknown therapeutic avenues for MS.

Explore more research

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Muted blue and clay ribbons curve across an off-white background, wrapped in soft layers of varying thickness.
Planned MS study will test scans to track worsening

11/16/2026

A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS

Read More
Brain outline filled with fine, branching nerve fibers on an off-white background.
In relapsing MS, Mavenclad users' thinking scores rose

11/14/2026

In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.

Read More
Two views of spinal cord nerve endings, with fewer chemical particles around the endings on the right.
Lab drug cut chemical release in MS-like mouse tissue

11/15/2026

In tissue from mice with an MS-like disease, a lab drug reduced excess chemical release from nerve e

Read More
Two paper paths meet at an open junction, surrounded by layered shapes in muted colors.
When older adults with MS should stop drugs remains unclear

11/15/2026

A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older

Read More
A winding path links a DNA strand and a partly broken ring in a simple two-color print.
Review explores how immune genes may shape MS damage

11/13/2026

A review compares MS with harmful drug reactions and proposes ways to test how immune genes, lasting

Read More
Two differently colored molecular shapes near immune cells and a myelinated nerve fiber on a pale background.
Review links vitamin D and vitamin A immune signals to MS

11/13/2026

This review examines how vitamin D and vitamin A signals shape immune activity in MS and other disea

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.